Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 PB Ratio is 0.89 as of Sep. 02, 2026, which is 33% above its 10-year median of 0.67. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 918 Drug Manufacturers companies, Jacobson Pharma ranks better than 80.17% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-02), Jacobson Pharma's share price is HK$1.035. Jacobson Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was HK$1.16. Hence, Jacobson Pharma's PB Ratio of today is 0.89.
Good Sign:
Jacobson Pharma Corp Ltd stock PB Ratio (=0.9) is close to 1-year low of 0.86.
The historical rank and industry rank for Jacobson Pharma's PB Ratio or its related term are showing as below:
HKSE:02633'
s PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.67 Max: 2.13
Current: 0.89
During the past 13 years, Jacobson Pharma's highest PB Ratio was 2.13. The lowest was 0.26. And the median was 0.67.
HKSE:02633's PB Ratio is ranked better than 80.17% of 918
companies
in the Drug Manufacturers industry
Industry Median: 2
vs HKSE:02633: 0.89
During the past 12 months, Jacobson Pharma's average Book Value Per Share Growth Rate was -5.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Jacobson Pharma was 36.30% per year. The lowest was -6.90% per year. And the median was 3.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jacobson Pharma PB Ratio Related Terms
Jacobson Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Jacobson Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jacobson Pharma (HKSE:02633) has a PB Ratio of 0.89 as of Sep. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jacobson Pharma and its competitors. This is 33% above median its historical median of 0.67. Over the past decade, Jacobson Pharma's PB Ratio has ranged from 0.26 to 2.13. According to the industry distribution chart, Jacobson Pharma ranks #182 out of 918 companies in the Drug Manufacturers industry, placing it in the top 19.8%.
Is Jacobson Pharma's PB Ratio too high?
Jacobson Pharma's current PB Ratio of 0.89 is 33% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.13. The Drug Manufacturers industry median PB Ratio is 2.00. Jacobson Pharma's value of 0.89 is 55.5% below this industry median. Based on the distribution chart, Jacobson Pharma ranks #182 out of 918 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #182 out of 918 companies for PB Ratio. This places Jacobson Pharma in the top 20% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.00. Jacobson Pharma's value of 0.89 is 55.5% below this benchmark. Historically, Jacobson Pharma's own PB Ratio has ranged from 0.26 to 2.13 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 2.00, Jacobson Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 2.00, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current PB Ratio of 0.89 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current PB Ratio is 0.89, which is 33% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current PB Ratio is 0.89, which is 33% above median its 10-year median of 0.67 and 55.5% below the Drug Manufacturers industry median of 2.00. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current PB Ratio is 0.89 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
PB Ratio: 0.89 (33% above median its 10-year median of 0.67)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 55.5% below the Drug Manufacturers median (#182 of 918)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
